Future research should prioritize the development of therapeutic strategies, such as CD2 agonists, to restore CD58 expression in hematological tumors or to circumvent the CD2-CD58 axis to target CD58- immuno-resistant cancer cells. This evidence concerns the gene CD58 and hematopoietic and lymphoid cell neoplasm.